Irinotecan pharmacogenetics: a finished puzzle?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it.

1. Irinotecan-induced toxicity pharmacogenetics: an umbrella review of systematic reviews and meta-analyses.The pharmacogenomics journal · 2017
   Pooled it
2. Therapeutic Effects of Ceranib-2 and Irinotecan Combination on Colon Cancer.Current issues in molecular biology · 2026
   Article
3. Value of plasma SN-38 levels and DPD activity in irinotecan-based individualized chemotherapy for advanced colorectal cancer with heterozygous type UGT1A1Cancer management and research · 2018
   Article
4. ABC transporter polymorphisms are associated with irinotecan pharmacokinetics and neutropenia.The pharmacogenomics journal · 2018
   Article
5. Puerarin increases the chemosensitivity of hepatocellular carcinoma cells.Oncology letters · 2017
   Article
6. Treatment mechanism of matrine in combination with irinotecan for colon cancer.Oncology letters · 2017
   Article
7. Update on the role of nanoliposomal irinotecan in the treatment of metastatic pancreatic cancer.Therapeutic advances in gastroenterology · 2017
   Review
8. Different schedules of irinotecan administration: A meta-analysis.Molecular and clinical oncology · 2016
   Article
9. Irinotecan, a key chemotherapeutic drug for metastatic colorectal cancer.World journal of gastroenterology · 2015
   Review

Corrections and comments

• Comment on
  Dose-finding and pharmacokinetic study to optimize the dosing of irinotecan according to the UGT1A1 genotype of patients with cancer.2014

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as